CL2021003303A1 - Tratamiento para sinucleinopatías. - Google Patents

Tratamiento para sinucleinopatías.

Info

Publication number
CL2021003303A1
CL2021003303A1 CL2021003303A CL2021003303A CL2021003303A1 CL 2021003303 A1 CL2021003303 A1 CL 2021003303A1 CL 2021003303 A CL2021003303 A CL 2021003303A CL 2021003303 A CL2021003303 A CL 2021003303A CL 2021003303 A1 CL2021003303 A1 CL 2021003303A1
Authority
CL
Chile
Prior art keywords
synucleinopathies
treatment
administering
treating
compound
Prior art date
Application number
CL2021003303A
Other languages
English (en)
Inventor
Nitin Krishnaji Damle
Andrew Michael Goldfine
Sanjaykumar Nandlal Mandhane
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of CL2021003303A1 publication Critical patent/CL2021003303A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para tratar o prevenir sinucleinopatías en un sujeto humano que comprende administrar una cantidad terapéuticamente eficaz de un compuesto de Fórmula 1, o su sal farmacéuticamente aceptable.
CL2021003303A 2019-06-11 2021-12-10 Tratamiento para sinucleinopatías. CL2021003303A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201921023164 2019-06-11

Publications (1)

Publication Number Publication Date
CL2021003303A1 true CL2021003303A1 (es) 2022-08-19

Family

ID=71094647

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003303A CL2021003303A1 (es) 2019-06-11 2021-12-10 Tratamiento para sinucleinopatías.

Country Status (14)

Country Link
US (1) US20220257582A1 (es)
EP (1) EP3982964A1 (es)
JP (1) JP2022536331A (es)
KR (1) KR20220024463A (es)
CN (1) CN114040763A (es)
AU (1) AU2020292703A1 (es)
BR (1) BR112021024835A2 (es)
CA (1) CA3142899A1 (es)
CL (1) CL2021003303A1 (es)
EA (1) EA202193211A1 (es)
IL (1) IL288797A (es)
MA (1) MA56179A (es)
MX (1) MX2021015390A (es)
WO (1) WO2020250133A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214314A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Vodobatinib for reducing progression of parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057165A2 (en) 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
US20060128720A1 (en) 2002-03-21 2006-06-15 Kufe Donald W Inhibition of cell death responses induced by oxidative stress
US20050043264A1 (en) 2003-07-01 2005-02-24 Jyh-Lyh Juang Methods of inhibiting neurodegenerative disease
US8618063B2 (en) 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy
KR101892574B1 (ko) 2011-01-21 2018-08-28 썬 파마 어드밴스트 리서치 컴패니 리미티드 디아릴아세틸렌 히드라지드 함유 티로신 키나제 억제제
BR112013024171A2 (pt) 2011-04-07 2016-12-13 Ariad Pharma Inc método para o tratamento e prevenção de uma condição neurodegenerativa
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
MY193754A (en) 2016-06-02 2022-10-27 Sun Pharma Advanced Res Co Ltd Treatment for parkinson's disease

Also Published As

Publication number Publication date
CN114040763A (zh) 2022-02-11
EP3982964A1 (en) 2022-04-20
IL288797A (en) 2022-02-01
MA56179A (fr) 2022-04-20
WO2020250133A1 (en) 2020-12-17
EA202193211A1 (ru) 2022-03-30
KR20220024463A (ko) 2022-03-03
CA3142899A1 (en) 2020-12-17
MX2021015390A (es) 2022-01-24
US20220257582A1 (en) 2022-08-18
AU2020292703A1 (en) 2022-01-27
BR112021024835A2 (pt) 2022-01-18
JP2022536331A (ja) 2022-08-15

Similar Documents

Publication Publication Date Title
EP4331677A3 (en) Methods of treating feline coronavirus infections
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MX2021013934A (es) Compuestos y metodos para el tratamiento de covid-19.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
AR060089A1 (es) Tratamiento del dolor
AR119158A1 (es) Tratamientos de angioedema hereditario
AR119159A1 (es) Tratamientos de angioedema
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
WO2020033838A3 (en) Treatment of egfr-mutant cancer
WO2018102687A3 (en) Combination therapy for treating cancer
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
CL2022000781A1 (es) Tratamientos cognitivos medicinales
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
WO2020128614A8 (en) Method for treating interstital lung disease
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS